» Articles » PMID: 16996250

Body Weight and Self-esteem in Patients with Schizophrenia Evaluated with B-WISE

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2006 Sep 26
PMID 16996250
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metabolic abnormalities and weight gain are an important problem in patients with schizophrenia. An instrument to evaluate body image and self-esteem related to weight has recently been developed (B-WISE). The first objective was to evaluate whether the findings of the original validation study could be confirmed in a European sample. The second objective was to explore the association of B-WISE scores with the metabolic syndrome and glucose abnormalities.

Methods: A Dutch translation of B-WISE was tested in a large sample of patients with schizophrenia (n=300) who underwent an extensive metabolic screening.

Results: The original findings with B-WISE were confirmed in an independent sample. Scores on B-WISE differed significantly as a function of BMI. Scores on B-WISE also differentiated patients with and without the metabolic syndrome and glucose abnormalities. Patients experiencing a recent weight gain had lower self-esteem and poorer psychosocial adaptation.

Conclusion: B-WISE could be a useful instrument to evaluate the subjective psychosocial consequences associated with current weight and weight gain in patients with schizophrenia.

Citing Articles

Metabolic profile in first episode drug naïve patients with psychosis and its relation to cognitive functions and social cognition: a case control study.

Sayed S, Gomaa S, Alhazmi A, ElKalla I, Khalil D Sci Rep. 2023; 13(1):5435.

PMID: 37012300 PMC: 10070352. DOI: 10.1038/s41598-023-31829-9.


Twelve-month outcomes in overweight/obese users with mental disorders following a multi-element treatment including diet, physical activity, and positive thinking: The real-world "An Apple a Day" controlled trial.

Giusti L, Bianchini V, Aggio A, Mammarella S, Salza A, Necozione S Front Psychiatry. 2022; 13:903759.

PMID: 36081460 PMC: 9445251. DOI: 10.3389/fpsyt.2022.903759.


An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder.

Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf M, Silverman B Neuropsychiatr Dis Treat. 2021; 17:2885-2904.

PMID: 34526769 PMC: 8437420. DOI: 10.2147/NDT.S313840.


Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese.

Zhang Q, He H, Bai X, Jiang L, Chen W, Zeng X Front Psychiatry. 2021; 12:702720.

PMID: 34305687 PMC: 8298856. DOI: 10.3389/fpsyt.2021.702720.


Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia.

MacKenzie N, Kowalchuk C, Agarwal S, Costa-Dookhan K, Caravaggio F, Gerretsen P Front Psychiatry. 2018; 9:622.

PMID: 30568606 PMC: 6290646. DOI: 10.3389/fpsyt.2018.00622.